Cargando…

Recent Developments in Preclinical DNA Vaccination

The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuda, Kenji, Wada, Yoshiyuki, Shimada, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494203/
https://www.ncbi.nlm.nih.gov/pubmed/26344468
http://dx.doi.org/10.3390/vaccines2010089
_version_ 1782380043297619968
author Okuda, Kenji
Wada, Yoshiyuki
Shimada, Masaru
author_facet Okuda, Kenji
Wada, Yoshiyuki
Shimada, Masaru
author_sort Okuda, Kenji
collection PubMed
description The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
format Online
Article
Text
id pubmed-4494203
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44942032015-08-31 Recent Developments in Preclinical DNA Vaccination Okuda, Kenji Wada, Yoshiyuki Shimada, Masaru Vaccines (Basel) Review The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here. MDPI 2014-01-13 /pmc/articles/PMC4494203/ /pubmed/26344468 http://dx.doi.org/10.3390/vaccines2010089 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Okuda, Kenji
Wada, Yoshiyuki
Shimada, Masaru
Recent Developments in Preclinical DNA Vaccination
title Recent Developments in Preclinical DNA Vaccination
title_full Recent Developments in Preclinical DNA Vaccination
title_fullStr Recent Developments in Preclinical DNA Vaccination
title_full_unstemmed Recent Developments in Preclinical DNA Vaccination
title_short Recent Developments in Preclinical DNA Vaccination
title_sort recent developments in preclinical dna vaccination
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494203/
https://www.ncbi.nlm.nih.gov/pubmed/26344468
http://dx.doi.org/10.3390/vaccines2010089
work_keys_str_mv AT okudakenji recentdevelopmentsinpreclinicaldnavaccination
AT wadayoshiyuki recentdevelopmentsinpreclinicaldnavaccination
AT shimadamasaru recentdevelopmentsinpreclinicaldnavaccination